The published evidence for the use of PP in AD is currently limited, and preliminary data from the recently concluded phase IIb/III Alzheimer Management by Albumin Replacement (AMBAR) study are available in abstract form, but has not yet been published in a peer-reviewed journal. The gene discussed is ALB; the disease is Alzheimer disease.